You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER3

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer Trial (HER3-DXd)

Available
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
  • (no location specified)
Oct 17, 2023

Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Patritumab deruxtecan
  • (no location specified)
May 9, 2023

HER3 Expression in Non-Small Cell Lung Cancer

Recruiting
  • Non-small Cell Lung Cancer
  • Archival tissue specimen and immunohistochemistry staining
  • Miami, Florida
  • +1 more
Mar 14, 2023

HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive

Recruiting
  • HER2-positive Breast Cancer
  • Acquisition of blood samples and tumour tissue samples (biopsies)
  • Brighton, United Kingdom
  • +1 more
Nov 9, 2022

Triple Negative Breast Cancer, HER2-negative Breast Cancer Trial in Tampa (HER2 - primed Dendritic cells, HER3 - primed

Recruiting
  • Triple Negative Breast Cancer
  • HER2-negative Breast Cancer
  • HER2 - primed Dendritic cells
  • HER3 - primed Dendritic cells
  • Tampa, Florida
    Moffitt Cancer Center
Jan 10, 2023

Breast Cancer Trial (Patritumab deruxtecan, Chemotherapy, Letrozole)

Recruiting
  • Breast Cancer
  • Patritumab deruxtecan
  • +2 more
  • Barcelona, Spain
    Hospital Clinic de Barcelona
Nov 28, 2022

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Santa Monica, California
  • +13 more
Feb 1, 2023

Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell Vaccine)

Recruiting
  • Leptomeningeal Disease
  • +2 more
  • Dendritic Cell Vaccine
  • Tampa, Florida
    Moffitt Cancer Center
Apr 11, 2023

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Locally Advanced or Metastatic Epithelial Tumor Trial in Guangzhou (SI-B001)

Active, not recruiting
  • Locally Advanced or Metastatic Epithelial Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 14, 2022

NSCLC, Pancreatic Cancer, Locally Advanced Solid Tumor Trial in Sydney (HMBD-001, Docetaxel, Nab-paclitaxel)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 16, 2023

Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer Trial in London, Oxford (HMBD-001)

Recruiting
  • Bladder Cancer
  • +13 more
  • London, United Kingdom
  • +1 more
Dec 13, 2021

Advanced Solid Tumors With HER2 Abnormalities, Advanced Solid Tumors With HER3 Abnormalities Trial in Worldwide (TAS0728)

Active, not recruiting
  • Advanced Solid Tumors With HER2 Abnormalities
  • Advanced Solid Tumors With HER3 Abnormalities
  • Duarte, California
  • +7 more
Dec 9, 2021

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

Metastatic Breast Cancer Trial in Japan, United States (Patritumab Deruxtecan)

Active, not recruiting
  • Metastatic Breast Cancer
  • Patritumab Deruxtecan
  • Newnan, Georgia
  • +25 more
Dec 5, 2022

Breast Cancer Trial in Spain (U3 1402)

Recruiting
  • Breast Cancer
  • U3 1402
  • Badalona, Barcelona, Spain
  • +9 more
Apr 1, 2022

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

Active, not recruiting
  • HER2-positive Breast Cancer
  • PIK3CA analysis
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

Not yet recruiting
  • Esophageal Squamous Carcinoma
  • HER-2 Protein Overexpression
  • (no location specified)
Sep 24, 2023

Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)

Enrolling by invitation
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Olga
Jun 19, 2023

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

NRG1, NRG1 Fusion, Pancreatic Cancer Trial (MCLA-128)

Available
  • NRG1
  • +11 more
  • (no location specified)
Jul 21, 2021